Two-Session CME With ABO MOC Webinar Series

Join us for this two-session CME With ABO MOC webinar series on the latest updates in the treatment of neovascular retinal diseases. Each session will be offered twice and will feature a live faculty question-and-answer session. Register now to save your virtual seat!

Session on Extending the Duration of Therapy

Thursday, March 25, 2021 | 8:00 pm – 9:15 pm ET – Click here to register
or
Saturday, April 10, 2021 | 11:00 am – 12:15 pm ET – Click here to register

Topics

  • The Burden of Treatment: A Review of the Issues Surrounding the Treatment of Neovascular Retinal Disease
  • Persistent Retinal Fluid Following Treatment: How Much Fluid Should We Tolerate?
  • Assessing Agents With Novel Mechanisms of Action and Targets
  • LIVE Question & Answer

Session on Options for Sustained Delivery

Saturday, March 27, 2021 | 11:00 am – 12:15 pm ET – Click here to register
or
Wednesday, April 7, 2021 | 8:00 pm – 9:15 pm ET – Click here to register

Topics

  • Sustained Delivery: An Overview of Options for Neovascular Disease
  • A Closer Look at Gene Therapy
  • Sustained Delivery: A Closer Look at the PDS Implant
  • LIVE Question & Answer

Target Audience

The intended audience for this activity is comprehensive ophthalmologists, retinal specialists and other health care professionals involved in the management of patients with retinal diseases.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden associated with current therapies used for the treatment of neovascular retinal diseases.
  • Assess the long-term effects of anti-VEGF therapy on vision, the potential for complications, and patient outcomes.
  • Summarize the evidence demonstrated in major clinical trials regarding treatment protocols and their application to real-world practice in the treatment of neovascular retinal diseases.
  • Examine the role of persistent retinal fluid in determining response to treatment in neovascular retinal diseases.
  • Evaluate new and emerging modalities that may reduce the burden of anti-VEGF therapy in neovascular retinal diseases.
  • Describe emerging delivery systems that allow for extended intervals between treatment for neovascular retinal diseases.

For more session-specific CME information, please visit the registration sites.